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cense.Abstract The willow tree is a symbolic medicinal plant that has been associated with the discovery
of aspirin, chemically known as acetylsalicylic acid, or salicylate, which still offers surprises as a
revival drug. The philosophical perspective of the signiﬁcance of the willow tree has been elaborated
since the Assyrians (4000 BC) and Sumerians (3500 BC), who were aware of its medicinal merits. In
1838, the main pharmacologically active ingredient of willow, the salicin structure was elucidated by
hydrolysis to comprise D-glucose and salicyl alcohol. These uncovered new perspectives, which
eventually lead to the discovery of aspirin.
ª 2010 King Saud University. Open access under CC BY-NC-ND license.1. Introduction
Over a century, numerous articles have been published on the
discovery of aspirin, its profound association to willow tree as
well as on its pharmacological signiﬁcance (Mayer et al., 1949;
Le´vesque and Lafont, 2000; Jones, 2001; Mahdi et al., 2006).
Generally, medicinal plants have contributed profoundly to
the development of drugs known of today as to the concept
of complementary medicines, the most widely used form of
therapeutic intervention in the past to present. Indeed, many
well-deﬁned 20th century drugs were derived from herbality.
lsevierplants. Drugs including salicylic acid (Salix sp.), curare (Chon-
drodendron tomentosum), digitoxin (Digitalis purpurea), taxol
(Taxus brevifolia), and many others, are well-recognised drugs
derived from plants with pharmaceutical and clinical poten-
tials (Ackerknecht, 1973; Sumner, 2000; Dewick, 2002). Some
of the mentioned drugs were known even to many early
civilisations such as Assyrians and Sumerians (Anderson,
1977; Saggs, 1989; Mindell, 1992; Cunningham, 1996; Riddle,
1999). It is generally accepted that the pharmacological prop-
erties of medicinal plants are well-deﬁned by indigenous
people of each place worldwide.
Epidemiological and experimental data have demonstrated
the signiﬁcance of aspirin as a revival drug with multiple ther-
apeutic activities such as anti-pyretic and anti-inﬂammatory
action. Other epidemiological studies also revealed the signiﬁ-
cance of aspirin in cancer biology and its protective role
against various types of cancer (Baron, 2003). As aspirin is a
well-recognised drug, the willow tree has deeply rooted to pro-
foundly associate with its discovery. This review, therefore, fo-
cuses on the historical and philosophical perspectives of
aspirin discovery.
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aspirin
Traditionally, many ancient civilisations have used herbal rem-
edies to treat various conditions; willow (Salix sp.) is one of
them (for review see Barrett et al., 1999; Le´vesque and Lafont,
2000; Jones, 2001; Cragg and Newman, 2001). The willow tree
belongs to the Salicaceae family which includes three species:
Salix alba L., Salix pentandra L. and Salix purpurea L. Phar-
macologically, the willow exhibits anti-inﬂammatory, anti-
rheumatic, antipyretic, antidotic, antigesic, and antiseptic
properties (Barnes et al., 2002).
The chronological history of the discovery of willow as a
medicinal plant can be sorted into three stages: the clinical po-
tential of willow, structural elucidation of the phytotherapeutic
salicin, and the chemical synthesis of salicylic acid and aspirin.Table 1 Chronological investigations of willow tree for establishme
Period Figure in the ﬁeld
4000 BC Assyrians
3500 BC Sumerian
1300 BC Egyptians
605 BC Babylonians
500 BC Chinese healers
400 BC Hippocrates, a Greek Physician
0100 AC Dioscorides, a Greek Physician
1763 Edward Stone, an Oxfordshire Reverend
1828 Johann Buchner, Professor of
Pharmacology, University of Munich
1829 Henri Leroux, a French Pharmacist
1830 Gay-Lussac and Magendie
1838 Raﬀaele Piria, Italian Chemist
1852 Gerland H.
1853 Charles von Gerhardt, Professor of
Chemistry at Montpellier University
1859/1860 Hermann Kolbe and E. Lautemann a
German Chemists at Marburg University
1874 Hermann Kolbe and E. Lautemann a
German Chemists at Marburg University
1876 Thomas MacLagan, a Scottish Physician
1893 Felix Hoﬀman
1971 Sir John Vane, a British PharmacologistThese are summarised in Table 1. Generally, herbalists have
explored nature to assist its survival. Indeed plants have been
exploited for food as well as a source of cure for various med-
ical conditions. Early records of using the willow tree, as a
source of a medicinal plant, goes back to about 6000 years
ago. Indeed, other mammalian species, like monkeys are
known to consume plants with medicinal properties (Sumner,
2000). Previous experiences in developing a drug was inﬂu-
enced by the need to prevail over illness and mans experience
in seeing the beneﬁcial side of a plant. This concept prevails
at present, in combating rare diseases, like cancer. Although
it was difﬁcult for ancient people to regulate the dose of herbal
medicine to its effective level, failure and success were often ex-
pected. Nevertheless, the accumulation of knowledge has pro-
foundly contributed to the development of the norm associated
with the concept of herbal medicine as well as to the modernnt of aspirin development.
Clinical/chemical perspective
Used the extract of willow leaves for painful musculoskeletal
joint pain conditions as well as antipyretic drug (Jack, 1997;
Vane and Botting, 2003)
Described the use of willow leaves for various ailments such as
antipyretic drug (Jack, 1997; Vane and Botting, 1998)
Used willow leaves for joint pain and for the relief of pain and
inﬂammation associated with wounds and antipyretic drug
(Jack, 1997; Vane and Botting, 1998; Nunn, 1996)
Used the willow tree for treatment for fever, pain and
inﬂammation (Chevallier, 1996)
Remedy for various illness (Riddle, 1999)
Relieve pain in childbirth and for fever (Riddle, 1999)
Reduce inﬂammation (De Materia Medica Libri Quinque)
(Wells, 2003)
Carried the ﬁrst clinical trial of willow bark and used willow
powder to treat ague (Stone, 1763).
Extracted and puriﬁed salicin* from willow bark (Vane and
Botting, 1992)
Improved the puriﬁcation process and obtained salicin in
crystalline form for the ﬁrst time (Rainsford, 1984)
They showed that salicin was non-nitrogenous compound
(Vane and Botting, 1992)
Resolved the chemical structure of salicin as a glucosidic salicyl
alcohol. Then oxidized salicyl alcohol into salicylic acid (Piria,
1838)
First to prepare salicylic acid (Gerland, 1852)
Gave evidence that salicylic acid structure comprises phenol
and carboxylic group. He also developed acetylsalicylic acid, or
aspirin (Von Gerhardt, 1853; Vane and Botting, 1992)
Discovered the chemical structure of salicyl alcohol and
synthesised salicylic acid (Kolbe and Lautemann, 1860)
Industrial scale production of salicylic acid and end of willow
powder era use as remedy (Kolbe, 1874)
Tried willow extract powder on himself before administration
of a patient with acute rheumatism (Vane and Botting, 1992)
Synthesised aspirin by acetylating the hydroxyl group of
salicylic acid at the ortho position (Sneader, 2000)
He proved the anticoagulant properties of aspirin by blocking
the biosynthesis of prostaglandin, the pain messengers. He
suggested that aspirin may reduce the risk of cardiovascular
disease which led to use low-dose aspirin as a preventative
measure in various cardiac conditions (Vane, 1971; Vane and
Botting, 1992, 1998)
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Figure 3 Acetylation of salicylic acid.
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methodologies have succeeded to standardise and predict the
biological activities of herbal compositions (Kung et al., 2003).
The word salicin is derived from the Latin name for the wil-
low, salix. Salicin is a white bitter-tasting powder can be ob-
tained by aqueous extraction of mainly willow bark and
leaves. The other names for salicin are: b-D-glucopyranoside;
2-(hydroxymethyl)phenyl; 2-(hydroxymethyl)phenyl; 2-(hydro-
xymethyl)phenyl-b-D-glucopyranoside; salicine; salicoside; sal-
icyl alcohol glucoside; and saligenin-b-D-glucopyranoside.
Herbalists demonstrated the signiﬁcance of the willow tree
as a medicinal plant to treat patients with various medicinal
conditions like fever and pain. The break through in identify-
ing the pharmacological active compound, salicin (the Latin
name for the willow), was made by the Italian chemist Raffaele
Piria in 1935 (Piria, 1838). He identiﬁed the chemical structure
of salicin as 2-(hydroxymethyl)phenyl-1-b-D-glucopyranoside
according to an acid hydrolysis experiment of salicin that
claimed to yield pure salicyl alcohol (2-hydroxymethyl phenol)
and D-glucose moiety (Fig. 1). Salicin also hydrolyzes in the
gastrointestinal tract to give D-glucose and salicyl alcohol
(Fig. 1). Upon absorption, salicyl alcohol is oxidized into sal-
icylic acid and other salicylates compounds such as saligenin,
salicyluric acid, salicyl glucuronides, and gentisinic acid which
all are eliminated through the kidney (Chrubasik and Shvartz-
man, 1999; Chrubasik and Eisenberg, 2004). A number of
other scientists, like Johann Buchner and Henri Leroux also
extracted salicin from willow but was used for clinical trials
to treat rheumatism and other related illnesses (Leroux,
1830; Rainsford, 1984; Gross and Greenberg, 1948; Bekemeier,
1977; Vane and Botting, 1992).
The nearest step in elucidating the chemical structure of sal-
icylic acid, the aspirin precursor, was achieved when salicyl
alcohol compound was chemically oxidized at the benzyl hy-
droxyl group to yield salicylic acid. The structure of salicylic
acid was identical to an authentic sample, obtained from the
oxidation of salicyl aldehyde (Fig. 2). The sample of salicylHydrolysis
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OHO
HO
Salicylic Acid
HO
HO
Salicyl Aldehyde
Oxidation
Figure 2 Oxidation of salicyl aldehyde into their acid derivative.aldehyde was also extracted from the meadow sweet ﬂowers
(Filipendula ulmaria, syn. Spiraea ulmaria), by the Swiss phar-
macist, Pagenstecher as early as 1835 who passed it to the Ger-
man chemist, Lowig, for oxidation (Fluckinger, 1888;
Rainsford, 1984; Wichtl and Bisset, 1994). S. ulmaria ﬂower
was also used during the middle ages as analgesic and anti-
inﬂammatory agent. Salicylic acid was then recognised as the
pharmacologically active discovery of acetylsalicylic acid, the
analgesic drug now commonly known as aspirin (Bradley,
1992; Wichtl and Bisset, 1994).
Salicylic acid was prepared chemically by Kolbe and Laute-
mann (1860) (Jourdier, 2003; Flieger, 2004), which led to the
establishment of large commercial production (the Heyden
Chemical Company). However, due to the irritant characteris-
tics of salicylic acid to the upper gastrointestinal tract, which
caused Felix Hoffman’s father to suffer from the medication
of his arthritis, Felix converted salicylic acid into acetylsalicylic
acid to reduce this side effect (Fig. 3). Acetylsalicylic acid was
then marketed in 1899 under the trademark name aspirin.
The pharmacological properties of aspirin were elaborated
in 1960s. Collier (1969a,b) analysed the inhibition effect of
some underline cellular mechanism by aspirin and other re-
lated drugs. Piper and Vane (1969) discovered the inhibition
effect of aspirin on prostaglandin synthesis from archidonic
acid, by presenting evidence of a substance called rabbit aorta,
which consists mainly of thromboxane A2 and to some extent
of the endoperoxides PGG2 and PGH2. Eleven years later,
Vane (1971) showed that the synthesis of prostaglandin re-
duced by salicylate in cell-free homogenates of lung tissue.
Vane and Botting (2003) and others (Picot et al., 1994; Loll
et al., 1995) illustrated the structure and the mechanism of ac-
tion of aspirin. It inhibits both cyclooxygenase-1 (Cox-1) and
cyclooxygenase-2 (Cox-2) by cross-acetylation of serine moiety
at the active site of the enzyme (Higgs and Vane, 1983; Hla
and Nelson, 1992; Herschman, 1996). Later, epidemiological
studies have led to generate a direct association between aspi-
rin (and other non-esteroidal anti-inﬂammatory drugs) and
cancer risk (Baron, 2003). Aspirin and other salicylates have
also shown an effective protective activities against particularly
colon cancer (Thun et al., 1991; Funkhouser and Sharp, 1995;
Steven, 1995; Rosenberg et al., 1999).
3. The philosophy behind developing herbal willow for therapy
In the last section we looked at the ancient civilisations and
how they used natural drugs, such as salicin, in which, until
the end of the 1890s, the rationale development of aspirin
was archived (Cragg and Newman, 2001). The concept of the
long efforts contributed to the discovery of aspirin, has proved
the human ability for discovery despite the time and the space.
The discovery has often been accomplished by curious explor-
ers of nature. As part of acquiring knowledge they were
prompted to fulﬁl human needs and sustain health. Such talent
320 J.G. Mahdiproves the possibility of creating an immense stream of knowl-
edge that ﬂows through civilisations where each adds its best
ﬂavour. The collective efforts has generated a large bank of
information, which has not only led to an understanding of
which plant, or certain part of the plant, is more pharmacolog-
ically potential, but also led to cultivate the knowledge that
have been diversely categorised and documented as edible,
toxic, unpalatable, the unpleasant or medicinal (Sumner, 2000).
The willow tree, and many other herbal plants, is the sym-
bol of unseen bridges between nations to harmonise the purity
of humanity. The philosophy of herbal medicine was generally
pioneered by some ﬁgures that undoubtedly used observations
and analysis techniques to discover their surrounding. They
also used primitive clinical experimentation for investigating
the pharmacological effects of plants, which depended upon
trial and error process. Each has his own perception towards
the interrelationship between plants and human. Although
they share the same method which involves searching for ra-
tional explanations of events in the natural world. The philos-
ophy of exploring plants for remedies also reveals the concept
of association between man and nature, using analogy tech-
niques for investigations. This can be seen in the Reverend Ed-
ward Stone challenge in employing the willow bark for the
treatment of various ailments. The basic philosophy which
drove Reverend Stone to use willow bark as a remedy was
his observation that the bitter taste of the willow bark is very
similar to peruvian bark (Quinquina, source of quinine) bitter-
ness. This sensational observation made the philosopher, asso-
ciate the taste property of willow to the therapeutic potential
of peruvian bark which was a well-known remedy for parox-
ysms, fever from agues, malaria and rheumatism (Stone,
1763). His hypothesis for the similarities of the therapeutic ac-
tion of both barks was tested in a clinical trial study for ﬁve
years. In his study he used willow bark (S. alba) for treatment
of paroxysms and fever from agues, or malaria. He concluded
that the therapeutic activities of the willow bark which was
similar to peruvian bark people used for relevant ailments.
The philosophy of the herbal medicine evolution was also
found in ordinary people who were desperately seeking relief
for their pain. The discovery of the therapeutic potential of
willow tree in England in the middle of the eighteenth century
was achieved by an English man who accidentally chewed a
twig of willow tree, despite its extraordinary bitter taste; ﬁnd-
ing himself relieved from his arthritic pain (Sutcliffe and Dunn,
1992). People from different cultures learnt of the therapeutic
properties of plants. According to Louis Pasteur’s remark,
observation is concerned, chance favours only the prepared mind.
Such a notion may reﬂect the necessity of humans to survive
and the curiosity to discover its surrounding. Humans rely
on nature in both health and illness. Archaeological evidence
has revealed the considerable knowledge of healing by herbs
(Roberts and Manchester, 1995; Pavek et al., 2003). The skills
of humans in this respect are tremendous to excel light on the
therapeutic basis of various approaches associated with the
philosophy of herbal medicine.
The ancients believed that the form, colour and the shape of
the plants are closely associated to certain therapeutic virtue.
Hence, the Doctrine of Signatures by the Neapolitan philoso-
pher, Giambattista della Porta in the Middle Ages, evolved
to reﬂect the thought and the insight of people towards plants.
The Doctrine of Signatures dictates that the cures for diseases
would be found in the same areas where malady occurs.Accordingly, both the willow tree and agues can be found
abundantly in moist and wet conditions (Vane and Botting,
1992). This concept had perhaps lead MacLagan to believe fur-
ther that the association between plant and healing can be ex-
tended to include climate: A remedy for that disease would most
hopefully be looked for among those plants and trees whose
favorite habitat presented conditions analogous to those under
which the rheumatic miasma seemed most to prevail. A low-lying
damp locality, with a cold rather than warm climate gives the
conditions under which rheumatic fever is most readily produced
(MacLagan, 1876).
The doctoring of signatures also characterizes the medicinal
potential of plants according to the visible mark bore in plant
that reveal its intended use. White willow (S. alba) and quaking
aspen (Populus tremuloids), for example, were found to be effec-
tive for fever, based on the tremulous ﬂuttering of their leaves
and branches (Wilkinson, 1997; Barrett et al., 1999). White wil-
low has since been found to contain salicin, and subsequently
led to the discovery of aspirin (Wilkinson, 1997). The signatures
of many other plants were selected according to their shape
characteristics, e.g. heart-shaped leaf as a heart remedy, yellow
plant parts for treating hepatitis, etc. The notion of the theory
was used in various part of the world, like theMiddle East (Lev,
2002), China (Yubin, 2001), Africa and Europe (Stefano and
Paracelsus, 1994), despite whether plant bore signiﬁcant mar-
ker relevant to its medicinal use or not.
The main problem associated with the practicality of theSig-
nature of Doctrine theory was perhaps, the optimisation of the
active ingredients in willow and other plants, which requires
analytical techniques, that was not available at that time. Herb-
alists in the eightieth century started to elucidate the concept of
how to optimise dosage of a biologically active substance when
it is not chemically pure. The other challenge to the Doctrine of
Signatures theory was the variation of active substances in
medicinal plants, which is inﬂuenced by their natural sources,
as well as by ecological and environmental conditions. It is clear
to ecologists that plant produces salicylic acid in response to
pathogens and stress (Raskin, 1992; Hammond-Kosack and
Jones, 1996; Ryals et al., 1996; Durner et al., 1997; Wildermuth
et al., 2001). Challenges related to the variation of pharmaco-
logically active ingredients in medicinal plants have gradually
disappears with the improvement of technology and accumula-
tion of knowledge in medicinal plants.
4. Conclusion
The lessons that have been learnt from the historical perspec-
tive of the willow sheds light on the lore of native people and
their healers who have exploited their efforts to bring about
the wonderful drug, aspirin. Whereas, chemistry has eluci-
dated the chemical structures that lead to the discovery of
aspirin.
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